In 2010 ARIAD announced result from a Phase I study of<unk>  in patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). The study demonstrated that in chronic-phase CML patients treated with<unk> , 66 percent of patients in the trial achieved a major cytogenetic response, including 100 percent of patients who also had a T315I mutation. The PACE<unk>  Ph+ ALL and CML Evaluation) pivotal phase II trial started enrolling patients in September 2010 and is designed to provide definitive clinical data for regulatory approval in this setting. Good results were reported in December 2012. The EPIC (Evaluation of<unk>  versus Imatinib in CML) phase-III trial began in June 2012 and was halted on October 18, 2013.
Ponatinib
Neratinib
Tucatinib
Dasatinib
Fostamatinib
Imatinib
Lapatinib
Pemigatinib